Which of the following is NOT an indicated use of lomitapide?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Which of the following is NOT an indicated use of lomitapide?

Lomitapide works by inhibiting microsomal triglyceride transfer protein, which blocks the assembly and secretion of apoB-containing lipoproteins in the liver and intestine. This lowers the production of VLDL and LDL, reducing LDL-C and total cholesterol, and it is used as adjunct therapy in homozygous familial hypercholesterolemia to achieve lower LDL-C. Increasing HDL-C is not achieved by this mechanism, so this is not an indicated use. The other options reflect reductions in LDL-C or total cholesterol and the HoFH indication.

Lomitapide works by inhibiting microsomal triglyceride transfer protein, which blocks the assembly and secretion of apoB-containing lipoproteins in the liver and intestine. This lowers the production of VLDL and LDL, reducing LDL-C and total cholesterol, and it is used as adjunct therapy in homozygous familial hypercholesterolemia to achieve lower LDL-C. Increasing HDL-C is not achieved by this mechanism, so this is not an indicated use. The other options reflect reductions in LDL-C or total cholesterol and the HoFH indication.

More practice questions